Dexcom Inc (DXCM) 69.28 $DXCM DexCom Announces
Post# of 273283
Posted On: 04/22/2015 7:18:00 PM
Dexcom Inc (DXCM) 69.28 $DXCM
DexCom Announces Upcoming Conference Presentations
Business Wire - Wed Apr 22, 7:30AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
DXCM: 69.28 (-1.05)
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:00PM CDT
DexCom Inc (DXCM) recently announced that its G4 PLATINUM Continuous Glucose Monitoring (CGM) System with Share app will be available on Apple Watch.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), FLDM: 43.04 (-1.36), INGN: 36.39 (-0.04)
Watch for DexCom to Potentially Pullback After Gaining 4.45% Yesterday
Comtex SmarTrend(R) - Fri Apr 10, 4:48PM CDT
DexCom (NASDAQ XCM) traded in a range yesterday that spanned from a low of $65.02 to a high of $68.49. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $65.19 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DXCM: 69.28 (-1.05)
DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 10:06AM CDT
Shares of DexCom Inc. (DXCM) rallied to a new 52-week high of $65.19 on Apr 9, eventually closing a tad bit lower at $65.00.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), INGN: 36.39 (-0.04), LMNX: 16.34 (-0.01)
DexCom Schedules First Quarter 2015 Earnings Release and Conference Call for April 29, 2015 at 4:30 p.m. Eastern Time
Business Wire - Fri Apr 10, 7:30AM CDT
DexCom, Inc. (NASDAQ XCM) today announced that it plans to release its first quarter 2015 financial results after market close on Wednesday, April 29, 2015. Management will hold a conference call to review the company's first quarter 2015 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
DXCM: 69.28 (-1.05)
Dexcom(R) Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple Watch(TM)
Business Wire - Fri Apr 10, 7:00AM CDT
Dexcom, Inc., (NASDAQ XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that its Dexcom G4(R) PLATINUM Continuous Glucose Monitor System with Share(TM) will support the Apple Watch(TM) when it ships to customers on April 24. As the industry's first mobile-connected system, Dexcom CGM and its mobile apps, Share(TM)2 and Follow, are already approved by the FDA and allow both users and "followers" to view glucose data directly on their iPhone. The Apple Watch apps from Dexcom will now enable users to monitor glucose on the Apple Watch so that people with diabetes can discreetly view their own information while parents and caregivers can conveniently view a child or loved one's glucose data, giving them peace of mind and reassurance when they are apart.
DXCM: 69.28 (-1.05)
Blood Glucose Monitoring (BGM) Devices - Global Strategic Business Report 2015: Blood Glucose Strips, Blood Glucose Meters & Lancets
M2 - Wed Apr 01, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nsrxg2/blood_glucose) has announced the addition of the "Blood Glucose Monitoring (BGM) Devices - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Blood Glucose Monitoring (BGM) Devices in US$ Million by the following Product Segments: - Blood Glucose Strips - Blood Glucose Meters - Lancets The report profiles 83 companies including many key and niche players such as: - Abbott Diabetes Care, Inc. (US) - AgaMatrix, Inc. (US) - Arkray, Inc. (Japan) - Arkray USA, Inc. (US) - Bayer Healthcare (US) - Bionime Corp. (Taiwan) - B. Braun Melsungen AG (Germany) - DexCom, Inc. (US) - LifeScan, Inc. (US) - Medtronic (US) - Nipro Diagnostics, Inc. (US) - Nova Biomedical Corporation (US) - Roche Diagnostics Corp. (US) - Terumo Europe NV (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. COMPETITION 3. MARKET TRENDS, ISSUES AND DRIVERS 4. TECHNOLOGY INNOVATIONS & ADVANCEMENTS 5. CONTINUOUS GLUCOSE MONITORING SYSTEMS: A MACRO PERSPECTIVE 6. DIABETES AND BGM DEVICES: OVERVIEW 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 83 (including Divisions/Subsidiaries (97) - The United States (49) - Canada (4) - Japan (4) - Europe (20) - France (1) - Germany (4) - The United Kingdom (3) - Italy (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (16) - Latin America (1) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/ns...od_glucose
DXCM: 69.28 (-1.05), MDT: 78.01 (+0.93)
DexCom (DXCM) Is Today's Strong On High Volume Stock
at The Street - Mon Mar 16, 9:04AM CDT
Trade-Ideas LLC identified DexCom (DXCM) as a strong on high relative volume candidate
DXCM: 69.28 (-1.05)
Insider Trading Alert - ARCC, DXCM, And IILG Traded By Insiders
at The Street - Tue Mar 10, 9:45AM CDT
Stocks with insider trader activity include ARCC, DXCM, and IILG
DXCM: 69.28 (-1.05), ARCC: 17.14 (+0.08), IILG: 25.39 (+0.24)
5 Health Care Stocks to Trade for Breakout Gains in March
at The Street - Tue Mar 03, 6:08AM CST
Here's a technical look at five of the best breakout setups in the health care sector right now.
ZFGN: 39.06 (+0.36), DXCM: 69.28 (-1.05), EW: 140.87 (+0.39), GSK: 46.57 (-0.67), NVDQ: 12.43 (-0.37)
DexCom: Post Earnings Pullback To Offer Buying Opportunity
Andy Batts - at Seeking Alpha - Sat Feb 28, 12:33PM CST
DXCM: 69.28 (-1.05)
DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 8:54AM CST
DexCom Inc (DXCM) reported fourth-quarter 2014 EPS of 2 cents per share, which compares favorably with the Zacks Consensus Estimate of a loss of 3 cents and year-ago loss of 4 cents per share.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), LMNX: 16.34 (-0.01), AAPL: 128.62 (+1.71)
DexCom's (DXCM) CEO Kevin Sayer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 10:19PM CST
DXCM: 69.28 (-1.05)
DexCom beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 3:11PM CST
DXCM: 69.28 (-1.05)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 123.60 (+0.33), CSGP: 198.86 (-0.57), HK: 1.60 (-0.05), GPOR: 49.00 (-0.49), BLDP: 2.14 (-0.09), PRSS: 3.80 (-0.11), EAC: 4.36 (-0.17), GXP: 26.55 (-0.05), DXCM: 69.28 (-1.05), LHCG: 34.07 (-0.41), STAA: 9.01 (unch), ESRT: 18.12 (+0.01), PGTI: 11.49 (+0.02), ORIG: 6.96 (+0.06), CWT: 24.37 (+0.10), MCHX: 4.50 (+0.47), RGR: 53.67 (+0.12), CLUB: 6.36 (-0.02), MMLP: 36.75 (+0.61), AR: 41.95 (+0.57), IL: 10.10 (+0.12), FOE: 12.64 (-0.05), ARI: 17.05 (-0.05), ANIK: 38.68 (+0.05), FARO: 44.64 (-0.93), BWC: 32.55 (+0.17), ESV: 24.03 (+0.13), MELI: 138.04 (+1.09), EPAM: 67.99 (-0.16), OAS: 16.47 (-0.36), AWR: 39.42 (-0.09), BMRN: 121.08 (-0.16), SFM: 33.33 (-0.06), ELGX: 17.07 (+0.15), AEGN: 18.69 (+0.14), AREX: 8.15 (-0.30), MDVN: 128.88 (+0.29), AGO: 27.54 (+0.04), RIG: 16.85 (-0.18), GMED: 25.09 (-0.16), DRYS: 0.74 (unch), AMSG: 64.72 (-0.54), LGCY: 13.26 (-0.48), CHDN: 114.85 (-0.70), KW: 25.54 (+0.11), PVA: 7.03 (-0.15), PLKI: 56.99 (-0.03), RIGP: 14.78 (-0.40), LB: 91.13 (-1.10), CLVS: 85.04 (-1.36), SBY: 15.85 (+0.02), CEMP: 38.71 (-0.15), CHMT: 30.13 (+0.13), AVGO: 127.89 (+4.79), CRM: 67.71 (+0.33), EHTH: 11.44 (+0.07)
Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 11:10AM CST
We expect DexCom Inc. (DXCM) to post a narrower-than-expected loss figure when it reports fourth quarter and full year 2014 results on Feb 25.
IPXL: 49.58 (-0.40), ACAD: 38.55 (-0.20), DXCM: 69.28 (-1.05), HPTX: 45.96 (-0.18)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.06 (-0.01), AMRN: 2.34 (-0.05), HWAY: 18.99 (-0.08), HLS: 46.35 (+0.48), CYBX: 63.59 (+0.27), ESRX: 86.12 (+0.02), ECYT: 6.37 (unch), DXCM: 69.28 (-1.05), NSTG: 12.25 (-0.02), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), MDXG: 10.21 (-0.17), DEPO: 27.14 (+0.65), ANIK: 38.68 (+0.05), NKTR: 10.90 (+0.16), KERX: 11.52 (-0.15), ALIM: 4.92 (-0.09), EPZM: 19.45 (+0.45), AEGR: 25.65 (+0.06), MDRX: 12.29 (+0.11), ELGX: 17.07 (+0.15), NUVA: 43.38 (+0.10), HPTX: 45.96 (-0.18), GNMK: 10.51 (-0.22), MDVN: 128.88 (+0.29), HBIO: 6.06 (-0.29), ACAD: 38.55 (-0.20), ST: 58.27 (+0.21), RPTP: 10.56 (-0.17), FMI: 48.71 (-0.96), GMED: 25.09 (-0.16), JAZZ: 186.13 (-0.41), PTCT: 70.98 (unch), INFI: 14.71 (-0.28), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), NEO: 4.83 (-0.04), EXAS: 22.28 (+0.24), ALKS: 62.60 (-0.24), HTWR: 77.60 (-2.35), MNKD: 4.90 (-0.09), IPXL: 49.58 (-0.40), SQNM: 4.47 (+0.08), HALO: 16.03 (+0.15), ISIS: 66.26 (-0.03), CLVS: 85.04 (-1.36), BIO: 136.64 (+0.02), BIOS: 5.23 (+0.04), PCRX: 83.61 (-0.41)
Dexcom Announces Continued Partnership with NASCAR Driver Ryan Reed
Business Wire - Thu Feb 19, 7:30AM CST
Dexcom, Inc., (NASDAQ XCM), the leader in continuous glucose monitoring (CGM), announced today that they are continuing their partnership with NASCAR driver Ryan Reed, the face of the American Diabetes Association's national diabetes awareness initiative, Drive to Stop Diabetes(SM)presented by Lilly Diabetes. Through the collaboration, Dexcom will continue its support of Ryan Reed while reinforcing the partners' common quest of creating awareness of CGM among people with diabetes. The campaign highlights the importance of daily monitoring and tracking of glucose trends in the management of diabetes.
DXCM: 69.28 (-1.05)
Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 7:36AM CST
DexCom is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
DXCM: 69.28 (-1.05)
DexCom Schedules Fourth Quarter and Full Year 2014 Earnings Release and Conference Call for February 25, 2015 at 4:30 p.m. Eastern Time
Business Wire - Wed Feb 18, 7:30AM CST
DexCom, Inc. (NASDAQ XCM) today announced that it plans to release its fourth quarter and full year 2014 financial results after market close on Wednesday, February 25, 2015. Management will hold a conference call to review the company's fourth quarter and full year 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
DXCM: 69.28 (-1.05)
DexCom Announces Upcoming Conference Presentations
Business Wire - Wed Apr 22, 7:30AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences: DXCM: 69.28 (-1.05)
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:00PM CDT
DexCom Inc (DXCM) recently announced that its G4 PLATINUM Continuous Glucose Monitoring (CGM) System with Share app will be available on Apple Watch.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), FLDM: 43.04 (-1.36), INGN: 36.39 (-0.04)
Watch for DexCom to Potentially Pullback After Gaining 4.45% Yesterday
Comtex SmarTrend(R) - Fri Apr 10, 4:48PM CDT
DexCom (NASDAQ
XCM) traded in a range yesterday that spanned from a low of $65.02 to a high of $68.49. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $65.19 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DXCM: 69.28 (-1.05)
DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 10:06AM CDT
Shares of DexCom Inc. (DXCM) rallied to a new 52-week high of $65.19 on Apr 9, eventually closing a tad bit lower at $65.00.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), INGN: 36.39 (-0.04), LMNX: 16.34 (-0.01)
DexCom Schedules First Quarter 2015 Earnings Release and Conference Call for April 29, 2015 at 4:30 p.m. Eastern Time
Business Wire - Fri Apr 10, 7:30AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that it plans to release its first quarter 2015 financial results after market close on Wednesday, April 29, 2015. Management will hold a conference call to review the company's first quarter 2015 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference. DXCM: 69.28 (-1.05)
Dexcom(R) Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple Watch(TM)
Business Wire - Fri Apr 10, 7:00AM CDT
Dexcom, Inc., (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that its Dexcom G4(R) PLATINUM Continuous Glucose Monitor System with Share(TM) will support the Apple Watch(TM) when it ships to customers on April 24. As the industry's first mobile-connected system, Dexcom CGM and its mobile apps, Share(TM)2 and Follow, are already approved by the FDA and allow both users and "followers" to view glucose data directly on their iPhone. The Apple Watch apps from Dexcom will now enable users to monitor glucose on the Apple Watch so that people with diabetes can discreetly view their own information while parents and caregivers can conveniently view a child or loved one's glucose data, giving them peace of mind and reassurance when they are apart. DXCM: 69.28 (-1.05)
Blood Glucose Monitoring (BGM) Devices - Global Strategic Business Report 2015: Blood Glucose Strips, Blood Glucose Meters & Lancets
M2 - Wed Apr 01, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nsrxg2/blood_glucose) has announced the addition of the "Blood Glucose Monitoring (BGM) Devices - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Blood Glucose Monitoring (BGM) Devices in US$ Million by the following Product Segments: - Blood Glucose Strips - Blood Glucose Meters - Lancets The report profiles 83 companies including many key and niche players such as: - Abbott Diabetes Care, Inc. (US) - AgaMatrix, Inc. (US) - Arkray, Inc. (Japan) - Arkray USA, Inc. (US) - Bayer Healthcare (US) - Bionime Corp. (Taiwan) - B. Braun Melsungen AG (Germany) - DexCom, Inc. (US) - LifeScan, Inc. (US) - Medtronic (US) - Nipro Diagnostics, Inc. (US) - Nova Biomedical Corporation (US) - Roche Diagnostics Corp. (US) - Terumo Europe NV (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. COMPETITION 3. MARKET TRENDS, ISSUES AND DRIVERS 4. TECHNOLOGY INNOVATIONS & ADVANCEMENTS 5. CONTINUOUS GLUCOSE MONITORING SYSTEMS: A MACRO PERSPECTIVE 6. DIABETES AND BGM DEVICES: OVERVIEW 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 83 (including Divisions/Subsidiaries (97) - The United States (49) - Canada (4) - Japan (4) - Europe (20) - France (1) - Germany (4) - The United Kingdom (3) - Italy (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (16) - Latin America (1) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/ns...od_glucose
DXCM: 69.28 (-1.05), MDT: 78.01 (+0.93)
DexCom (DXCM) Is Today's Strong On High Volume Stock
at The Street - Mon Mar 16, 9:04AM CDT
Trade-Ideas LLC identified DexCom (DXCM) as a strong on high relative volume candidate
DXCM: 69.28 (-1.05)
Insider Trading Alert - ARCC, DXCM, And IILG Traded By Insiders
at The Street - Tue Mar 10, 9:45AM CDT
Stocks with insider trader activity include ARCC, DXCM, and IILG
DXCM: 69.28 (-1.05), ARCC: 17.14 (+0.08), IILG: 25.39 (+0.24)
5 Health Care Stocks to Trade for Breakout Gains in March
at The Street - Tue Mar 03, 6:08AM CST
Here's a technical look at five of the best breakout setups in the health care sector right now.
ZFGN: 39.06 (+0.36), DXCM: 69.28 (-1.05), EW: 140.87 (+0.39), GSK: 46.57 (-0.67), NVDQ: 12.43 (-0.37)
DexCom: Post Earnings Pullback To Offer Buying Opportunity
Andy Batts - at Seeking Alpha - Sat Feb 28, 12:33PM CST
DXCM: 69.28 (-1.05)
DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 8:54AM CST
DexCom Inc (DXCM) reported fourth-quarter 2014 EPS of 2 cents per share, which compares favorably with the Zacks Consensus Estimate of a loss of 3 cents and year-ago loss of 4 cents per share.
ABMD: 69.31 (-0.40), DXCM: 69.28 (-1.05), LMNX: 16.34 (-0.01), AAPL: 128.62 (+1.71)
DexCom's (DXCM) CEO Kevin Sayer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 10:19PM CST
DXCM: 69.28 (-1.05)
DexCom beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 3:11PM CST
DXCM: 69.28 (-1.05)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 123.60 (+0.33), CSGP: 198.86 (-0.57), HK: 1.60 (-0.05), GPOR: 49.00 (-0.49), BLDP: 2.14 (-0.09), PRSS: 3.80 (-0.11), EAC: 4.36 (-0.17), GXP: 26.55 (-0.05), DXCM: 69.28 (-1.05), LHCG: 34.07 (-0.41), STAA: 9.01 (unch), ESRT: 18.12 (+0.01), PGTI: 11.49 (+0.02), ORIG: 6.96 (+0.06), CWT: 24.37 (+0.10), MCHX: 4.50 (+0.47), RGR: 53.67 (+0.12), CLUB: 6.36 (-0.02), MMLP: 36.75 (+0.61), AR: 41.95 (+0.57), IL: 10.10 (+0.12), FOE: 12.64 (-0.05), ARI: 17.05 (-0.05), ANIK: 38.68 (+0.05), FARO: 44.64 (-0.93), BWC: 32.55 (+0.17), ESV: 24.03 (+0.13), MELI: 138.04 (+1.09), EPAM: 67.99 (-0.16), OAS: 16.47 (-0.36), AWR: 39.42 (-0.09), BMRN: 121.08 (-0.16), SFM: 33.33 (-0.06), ELGX: 17.07 (+0.15), AEGN: 18.69 (+0.14), AREX: 8.15 (-0.30), MDVN: 128.88 (+0.29), AGO: 27.54 (+0.04), RIG: 16.85 (-0.18), GMED: 25.09 (-0.16), DRYS: 0.74 (unch), AMSG: 64.72 (-0.54), LGCY: 13.26 (-0.48), CHDN: 114.85 (-0.70), KW: 25.54 (+0.11), PVA: 7.03 (-0.15), PLKI: 56.99 (-0.03), RIGP: 14.78 (-0.40), LB: 91.13 (-1.10), CLVS: 85.04 (-1.36), SBY: 15.85 (+0.02), CEMP: 38.71 (-0.15), CHMT: 30.13 (+0.13), AVGO: 127.89 (+4.79), CRM: 67.71 (+0.33), EHTH: 11.44 (+0.07)
Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 11:10AM CST
We expect DexCom Inc. (DXCM) to post a narrower-than-expected loss figure when it reports fourth quarter and full year 2014 results on Feb 25.
IPXL: 49.58 (-0.40), ACAD: 38.55 (-0.20), DXCM: 69.28 (-1.05), HPTX: 45.96 (-0.18)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.06 (-0.01), AMRN: 2.34 (-0.05), HWAY: 18.99 (-0.08), HLS: 46.35 (+0.48), CYBX: 63.59 (+0.27), ESRX: 86.12 (+0.02), ECYT: 6.37 (unch), DXCM: 69.28 (-1.05), NSTG: 12.25 (-0.02), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), MDXG: 10.21 (-0.17), DEPO: 27.14 (+0.65), ANIK: 38.68 (+0.05), NKTR: 10.90 (+0.16), KERX: 11.52 (-0.15), ALIM: 4.92 (-0.09), EPZM: 19.45 (+0.45), AEGR: 25.65 (+0.06), MDRX: 12.29 (+0.11), ELGX: 17.07 (+0.15), NUVA: 43.38 (+0.10), HPTX: 45.96 (-0.18), GNMK: 10.51 (-0.22), MDVN: 128.88 (+0.29), HBIO: 6.06 (-0.29), ACAD: 38.55 (-0.20), ST: 58.27 (+0.21), RPTP: 10.56 (-0.17), FMI: 48.71 (-0.96), GMED: 25.09 (-0.16), JAZZ: 186.13 (-0.41), PTCT: 70.98 (unch), INFI: 14.71 (-0.28), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), NEO: 4.83 (-0.04), EXAS: 22.28 (+0.24), ALKS: 62.60 (-0.24), HTWR: 77.60 (-2.35), MNKD: 4.90 (-0.09), IPXL: 49.58 (-0.40), SQNM: 4.47 (+0.08), HALO: 16.03 (+0.15), ISIS: 66.26 (-0.03), CLVS: 85.04 (-1.36), BIO: 136.64 (+0.02), BIOS: 5.23 (+0.04), PCRX: 83.61 (-0.41)
Dexcom Announces Continued Partnership with NASCAR Driver Ryan Reed
Business Wire - Thu Feb 19, 7:30AM CST
Dexcom, Inc., (NASDAQ
XCM), the leader in continuous glucose monitoring (CGM), announced today that they are continuing their partnership with NASCAR driver Ryan Reed, the face of the American Diabetes Association's national diabetes awareness initiative, Drive to Stop Diabetes(SM)presented by Lilly Diabetes. Through the collaboration, Dexcom will continue its support of Ryan Reed while reinforcing the partners' common quest of creating awareness of CGM among people with diabetes. The campaign highlights the importance of daily monitoring and tracking of glucose trends in the management of diabetes. DXCM: 69.28 (-1.05)
Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 7:36AM CST
DexCom is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
DXCM: 69.28 (-1.05)
DexCom Schedules Fourth Quarter and Full Year 2014 Earnings Release and Conference Call for February 25, 2015 at 4:30 p.m. Eastern Time
Business Wire - Wed Feb 18, 7:30AM CST
DexCom, Inc. (NASDAQ
XCM) today announced that it plans to release its fourth quarter and full year 2014 financial results after market close on Wednesday, February 25, 2015. Management will hold a conference call to review the company's fourth quarter and full year 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference. DXCM: 69.28 (-1.05)
(0)
(0)Scroll down for more posts ▼